Nadezda RADOJA

Biography

Dr. Nadezda Radoja joined NIA in August 2020 as a Senior Advisor for Regulatory Science in the Division of Neuroscience.  She has over twenty years of experience in various research and administrative roles in academia, the National Institutes of Health (NIH) and the Food and Drug Administration (FDA).  Prior to joining the NIA Dr. Radoja held a Team Leader position at the FDA, in the Center for Devices and Radiological Health (CDRH).  In this role she led a team of 9 scientific reviewers, responsible for pre-market applications and mandated post-market studies for in vitro diagnostic devices and implantable cardiovascular devices.  During her tenure at the FDA Dr. Radoja led over 200 regulatory submissions including face-to-face meetings with industry, academia and professional society organizations. In addition to her regular duties, she served as an advisor to the FDA Senior Medical Advisor for Digital Health, for the development of a novel PreCert regulatory program intended to revolutionize digital health regulation, in response to the 21st Century Cures Act. 

Dr. Radoja has extensive research expertise in molecular and cell biology and immunology, studying mechanisms of cellular senescence, DNA repair and cellular differentiation. She completed her PhD in molecular biology at the University of Belgrade and at New York University Medical Center. She received her post-doctoral training at Harvard University, the National Cancer Institute (NCI) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). 

After completing her post-doctoral training as a technology transfer specialist at NCI, Dr. Radoja held a technology transfer position at the University of Maryland Biotechnology Institute. In this role she led, negotiated and executed a wide range of technology transfer agreements, worked on developing patent strategies, educated scientists on the rules, regulations, and laws governing technology transfer and interacted with outside organizations, such as Technology Development Corporation (Maryland) organization (TEDCO) and angel investors, to generate future partnerships including sponsored research, licenses and other collaborations.